Evidence map›Paper›PMID 25821830›Full record

Trial reportBioMed research international2015

Survival of Mexican children with acute myeloid leukaemia who received early intensification chemotherapy and an autologous transplant.

Elva Jiménez-Hernández, María Teresa Dueñas-González, José Arellano-Galindo, María Elena Medrano-Ortíz-De-Zárate, Vilma Carolina Bekker-Méndez, Adolfina Berges-García, Karina Solís-Labastida, Berenice Sánchez-Jara, Héctor Manuel Tiznado-García, Ethel Zulie Jaimes-Reyes and 8 more

Abstract readClinical Trial
In one paragraph

Trial report in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. MiRNAs in Hematopoiesis and Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2023
    Review
  3. Article
  4. Article
  5. MiR-29 Induces K562 Cell Apoptosis by Down-Regulating FoxM1.Medical science monitor : international medical journal of experimental and clinical research · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Elva Jiménez-HernándezDepartamento de Hematología Pediátrica, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional "La Raza", Instituto Mexicano del Seguro Social (IMSS), Avenida Jacarandas Esquina Vallejo, S/N, Colonia La Raza, 02990 México, DF, Mexico.
María Teresa Dueñas-GonzálezDepartamento de Hematología Pediátrica, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional "La Raza", Instituto Mexicano del Seguro Social (IMSS), Avenida Jacarandas Esquina Vallejo, S/N, Colonia La Raza, 02990 México, DF, Mexico.
José Arellano-GalindoLaboratorio de Investigación, Hospital Infantil de México "Federico Gómez", Secretaría de Salud, Calle Doctor Marquez 162, Colonia Doctores, Delegación Cuauhtémoc, 06720 México, DF, Mexico.
María Elena Medrano-Ortíz-De-ZárateHospital de Oncología, Centro Médico Nacional "Siglo XXI", IMSS, Avenida Cuauhtemoc 330, 06720 México, DF, Mexico.
Vilma Carolina Bekker-MéndezUnidad de Investigación en Inmunología, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional "La Raza", Instituto Mexicano del Seguro Social (IMSS), Avenida Jacarandas Esquina Vallejo, S/N, Colonia La Raza, 02990 México, DF, Mexico.
Adolfina Berges-GarcíaDepartamento de Hematología Pediátrica, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional "La Raza", Instituto Mexicano del Seguro Social (IMSS), Avenida Jacarandas Esquina Vallejo, S/N, Colonia La Raza, 02990 México, DF, Mexico.
Karina Solís-LabastidaHematología Pediátrica, Centro Médico Nacional "Siglo XXI", IMSS, Avenida Cuauhtemoc 330, 06720 México, DF, Mexico.
Berenice Sánchez-JaraDepartamento de Hematología Pediátrica, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional "La Raza", Instituto Mexicano del Seguro Social (IMSS), Avenida Jacarandas Esquina Vallejo, S/N, Colonia La Raza, 02990 México, DF, Mexico.
Héctor Manuel Tiznado-GarcíaDepartamento de Hematología Pediátrica, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional "La Raza", Instituto Mexicano del Seguro Social (IMSS), Avenida Jacarandas Esquina Vallejo, S/N, Colonia La Raza, 02990 México, DF, Mexico.
Ethel Zulie Jaimes-ReyesDepartamento de Hematología Pediátrica, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional "La Raza", Instituto Mexicano del Seguro Social (IMSS), Avenida Jacarandas Esquina Vallejo, S/N, Colonia La Raza, 02990 México, DF, Mexico.
Xochiketzalli García-JiménezFacultad de Medicina, Universidad Nacional Autónoma de México, Avenida Universidad 3000, 04510 México, DF, Mexico.
Laura Espinoza-HernándezDepartamento de Hematología Pediátrica, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional "La Raza", Instituto Mexicano del Seguro Social (IMSS), Avenida Jacarandas Esquina Vallejo, S/N, Colonia La Raza, 02990 México, DF, Mexico.
Nora Nancy Núñez-VillegasDepartamento de Hematología Pediátrica, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional "La Raza", Instituto Mexicano del Seguro Social (IMSS), Avenida Jacarandas Esquina Vallejo, S/N, Colonia La Raza, 02990 México, DF, Mexico.
Sergio Franco-OrnelasDepartamento de Hematología Pediátrica, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional "La Raza", Instituto Mexicano del Seguro Social (IMSS), Avenida Jacarandas Esquina Vallejo, S/N, Colonia La Raza, 02990 México, DF, Mexico.
Ruy Xavier Pérez-CasillasDepartamento de Hematología Pediátrica, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional "La Raza", Instituto Mexicano del Seguro Social (IMSS), Avenida Jacarandas Esquina Vallejo, S/N, Colonia La Raza, 02990 México, DF, Mexico.
Octavio Martínez VillegasDepartamento de Hematología Pediátrica, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional "La Raza", Instituto Mexicano del Seguro Social (IMSS), Avenida Jacarandas Esquina Vallejo, S/N, Colonia La Raza, 02990 México, DF, Mexico.
Teresa Marin PalomaresDepartamento de Hematología Pediátrica, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional "La Raza", Instituto Mexicano del Seguro Social (IMSS), Avenida Jacarandas Esquina Vallejo, S/N, Colonia La Raza, 02990 México, DF, Mexico.
Juan Manuel Mejía-AranguréUnidad de Investigación en Epidemiología Clínica, UMAE Hospital de Pediatría, Centro Médico Nacional "Siglo XXI", IMSS, Avenida Cuauhtemoc 330, 4to Piso Edificio de la Academia Nacional de Medicina, 06720 México, DF, Mexico.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn Mexico and other developing countries, few reports of the survival of children with acute leukaemia exist. Objective. We aimed at comparing the disease-free survival of children with acute myeloid leukaemia who, in addition to being treated with the Latin American protocol of chemotherapy and an autologous transplant, either underwent early intensified chemotherapy or did not undergo such treatment. PROCEDURE: This was a cohort study with a historical control group, forty patients, less than 16 years old. Group A (20 patients), diagnosed in the period 2005-2007, was treated with the Latin American protocol of chemotherapy with an autologous transplant plus early intensified chemotherapy: high doses of cytarabine and mitoxantrone. Group B (20 patients), diagnosed in the period 1999-2004, was treated as Group A, but without the early intensified chemotherapy.

resultsRelapse-free survival for Group A was 90% whereas that for Group B it was 60% (P = 0.041). Overall survival for Group A (18, 90%) was higher than that for Group B (60%). Complete remission continued for two years of follow-up.

conclusionsRelapse-free survival for paediatric patients treated with the Latin American protocol of chemotherapy with an autologous transplant plus early intensified chemotherapy was higher than that for those who did not receive early intensified chemotherapy.

Indexed as

Antineoplastic AgentsChildChild, PreschoolCombined Modality TherapyFemaleHumansInfantLeukemia, Myeloid, AcuteLongitudinal StudiesMaleMexicoRisk FactorsStem Cell TransplantationSurvival RateSurvivorsTreatment OutcomeAntineoplastic Agents

Identifiers

PMID25821830
PMCPMC4363903

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.